{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:45:31Z","timestamp":1792215931724,"version":"4.4.0"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100032616","name":"Starr Cancer Consortium","doi-asserted-by":"publisher","award":["I16-0064"],"award-info":[{"award-number":["I16-0064"]}],"id":[{"id":"10.13039\/100032616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006094","name":"University of Delaware","doi-asserted-by":"publisher","award":["R25CA259244"],"award-info":[{"award-number":["R25CA259244"]}],"id":[{"id":"10.13039\/100006094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["101095604"],"award-info":[{"award-number":["101095604"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["825410"],"award-info":[{"award-number":["825410"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014630","name":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014630","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019937","name":"William Guy Forbeck Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101052444"],"award-info":[{"award-number":["101052444"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","award":["ZP-6177"],"award-info":[{"award-number":["ZP-6177"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA274291"],"award-info":[{"award-number":["U54CA274291"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA221704"],"award-info":[{"award-number":["U54CA221704"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA271915"],"award-info":[{"award-number":["R01CA271915"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004795","name":"Institut Universitaire de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007322","name":"Fox Chase Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015545","name":"Seerave Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["BC180476P1"],"award-info":[{"award-number":["BC180476P1"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["W81XWH2120034"],"award-info":[{"award-number":["W81XWH2120034"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["BC210945"],"award-info":[{"award-number":["BC210945"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-RHUS-0010"],"award-info":[{"award-number":["ANR-23-RHUS-0010"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-R4HC-0006"],"award-info":[{"award-number":["ANR-23-R4HC-0006"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-21-RHUS-0017"],"award-info":[{"award-number":["ANR-21-RHUS-0017"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["21- ESRE-0028"],"award-info":[{"award-number":["21- ESRE-0028"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-22-CE14-0066"],"award-info":[{"award-number":["ANR-22-CE14-0066"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-CE44-0030"],"award-info":[{"award-number":["ANR-23-CE44-0030"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017320","name":"Luke Heller Tec Pr2 Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Metabolism"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cmet.2026.09.015","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:40:21Z","timestamp":1792075221000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A context-dependent framework for targeting NAD metabolism in cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-8350","authenticated-orcid":false,"given":"Leire","family":"Arrizabalaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4674-7041","authenticated-orcid":false,"given":"Laura","family":"Santambrogio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-4405","authenticated-orcid":false,"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-8500","authenticated-orcid":false,"given":"Lorenzo","family":"Galluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-8778","authenticated-orcid":false,"given":"Aitziber","family":"Buqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmet.2026.09.015_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cmet.2015.05.023","article-title":"NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus","volume":"22","author":"Cant\u00f3","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib2","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aac4854","article-title":"NAD+ in aging, metabolism, and neurodegeneration","volume":"350","author":"Verdin","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cmet.2026.09.015_bib3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrm3376","article-title":"New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs","volume":"13","author":"Gibson","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cmet.2026.09.015_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-024-01994-5","article-title":"Mono-ADP-ribosylation, a MARylationmultifaced modification of protein, DNA and RNA: characterizations, functions and mechanisms","volume":"10","author":"Wu","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.cmet.2026.09.015_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev-biochem-082520-125411","article-title":"Understanding the function of mammalian sirtuins and protein lysine acylation","volume":"90","author":"Wang","year":"2021","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.cmet.2026.09.015_bib6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.cmet.2026.09.015_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41583-020-0269-3","article-title":"Programmed axon degeneration: from mouse to mechanism to medicine","volume":"21","author":"Coleman","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.cmet.2026.09.015_bib8","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41580-024-00752-w","article-title":"Regulation of and challenges in targeting NAD+ metabolism","volume":"25","author":"Migaud","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cmet.2026.09.015_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-nutr-112525-013335","article-title":"Mechanisms of NAD+ homeostasis in aging and disease","volume":"46","author":"McReynolds","year":"2026","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.cmet.2026.09.015_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.yjmcc.2024.07.008","article-title":"NAD metabolism and heart failure: Mechanisms and therapeutic potentials","volume":"195","author":"Walker","year":"2024","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.cmet.2026.09.015_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrneph.2017.5","article-title":"Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseases","volume":"13","author":"Hershberger","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.cmet.2026.09.015_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41580-020-00313-x","article-title":"NAD+ metabolism and its roles in cellular processes during ageing","volume":"22","author":"Covarrubias","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cmet.2026.09.015_bib13","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.cell.2025.03.011","article-title":"From geroscience to precision geromedicine: Understanding and managing aging","volume":"188","author":"Kroemer","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrc3340","article-title":"The NAD metabolome--a key determinant of cancer cell biology","volume":"12","author":"Chiarugi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib15","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","article-title":"Cancer cell metabolism and antitumour immunity","volume":"24","author":"De Martino","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cmet.2026.09.015_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s42255-019-0161-5","article-title":"NAD+ homeostasis in health and disease","volume":"2","author":"Katsyuba","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/s12950-025-00457-7","article-title":"NAD\u2009+ metabolism and function in innate and adaptive immune cells","volume":"22","author":"Mann","year":"2025","journal-title":"J. Inflamm. (Lond)"},{"key":"10.1016\/j.cmet.2026.09.015_bib18","doi-asserted-by":"crossref","first-page":"36334","DOI":"10.1074\/jbc.M508660200","article-title":"Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms","volume":"280","author":"Berger","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cmet.2026.09.015_bib19","doi-asserted-by":"crossref","first-page":"21767","DOI":"10.1074\/jbc.M110.213298","article-title":"Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation","volume":"286","author":"Nikiforov","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cmet.2026.09.015_bib20","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1126\/science.aad5168","article-title":"Biosensor reveals multiple sources for mitochondrial NAD+","volume":"352","author":"Cambronne","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cmet.2026.09.015_bib21","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/s42255-024-01174-w","article-title":"Subcellular NAD(+) pools are interconnected and buffered by mitochondrial NAD","volume":"6","author":"Hoyland","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41573-022-00415-5","article-title":"Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment","volume":"21","author":"Petroni","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cmet.2026.09.015_bib23","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1947601913507576","article-title":"Nicotinamide phosphoribosyltransferase in malignancy: a review","volume":"4","author":"Shackelford","year":"2013","journal-title":"Genes Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41586-019-1150-2","article-title":"NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling","volume":"569","author":"Chowdhry","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.09.015_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1269896","article-title":"Targeting NAD+ metabolism: dual roles in cancer treatment","volume":"14","author":"Yong","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cmet.2026.09.015_bib27","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1172\/JCI64264","article-title":"Mitochondrial complex I activity and NAD+\/NADH balance regulate breast cancer progression","volume":"123","author":"Santidrian","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cmet.2026.09.015_bib28","article-title":"NAD+ metabolism, stemness, the immune response, and cancer","volume":"6","author":"Navas","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cmet.2026.09.015_bib29","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.cell.2025.12.049","article-title":"Hallmarks of cancer-Then and now, and beyond","volume":"189","author":"Hanahan","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/carcin\/22.1.1","article-title":"Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity","volume":"22","author":"Tsutsumi","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cmet.2026.09.015_bib32","article-title":"NAPRT-mediated deamidated NAD biosynthesis enhances colon tissue resiliency and suppresses tumorigenesis","volume":"17","author":"Wu","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2026.09.015_bib33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.cell.2012.10.047","article-title":"The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism","volume":"151","author":"Sebasti\u00e1n","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101461","article-title":"SIRT7 facilitates CENP-A nucleosome assembly and suppresses intestinal tumorigenesis","volume":"23","author":"Liu","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.cmet.2026.09.015_bib35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.gendis.2020.08.007","article-title":"Hepatic SIRT6 deficit promotes liver tumorigenesis in the mice models","volume":"9","author":"Wang","year":"2022","journal-title":"Genes Dis."},{"key":"10.1016\/j.cmet.2026.09.015_bib36","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.cell.2016.04.033","article-title":"SIRT6 suppresses pancreatic cancer through control of Lin28b","volume":"165","author":"Kugel","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccr.2011.09.004","article-title":"SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC\/C activity","volume":"20","author":"Kim","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ccr.2009.11.023","article-title":"SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress","volume":"17","author":"Kim","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ccr.2008.09.001","article-title":"Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice","volume":"14","author":"Wang","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib40","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1097\/HEP.0000000000000314","article-title":"Hepatic mitochondrial NAD + transporter SLC25A47 activates AMPK\u03b1 mediating lipid metabolism and tumorigenesis","volume":"78","author":"Cheng","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.09.015_bib41","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.cell.2020.07.039","article-title":"Oxidative metabolism drives immortalization of neural stem cells during tumorigenesis","volume":"182","author":"Bonnay","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib42","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1038\/sj.onc.1207696","article-title":"Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia","volume":"23","author":"Mart\u00edn-Oliva","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.cmet.2026.09.015_bib43","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cmet.2021.04.003","article-title":"Evolving concepts in NAD+ metabolism","volume":"33","author":"Chini","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib44","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nrc3985","article-title":"The multifaceted functions of sirtuins in cancer","volume":"15","author":"Chalkiadaki","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","article-title":"Nucleotide metabolism: a pan-cancer metabolic dependency","volume":"23","author":"Mullen","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib46","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41568-021-00388-4","article-title":"Tumour fatty acid metabolism in the context of therapy resistance and obesity","volume":"21","author":"Hoy","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib47","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","article-title":"Targeting metabolism for cancer therapy","volume":"24","author":"Luengo","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.cmet.2026.09.015_bib48","first-page":"6648","article-title":"Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis","volume":"15","author":"Zhou","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.cmet.2026.09.015_bib49","article-title":"NAMPT and NAPRT, key enzymes in NAD salvage synthesis pathway, are of negative prognostic value in colorectal cancer","volume":"9","author":"Li","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib50","first-page":"1251","article-title":"Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil","volume":"26","author":"Bi","year":"2011","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cmet.2026.09.015_bib51","article-title":"Spatiotemporal multi-omics analysis uncovers NAD-dependent immunosuppressive niche triggering early gastric cancer","volume":"10","author":"Gao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cmet.2026.09.015_bib52","first-page":"522","article-title":"Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers","volume":"3","author":"Shackelford","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.cmet.2026.09.015_bib53","doi-asserted-by":"crossref","first-page":"99514","DOI":"10.18632\/oncotarget.20577","article-title":"NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis","volume":"8","author":"Lucena-Cacace","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cmet.2026.09.015_bib54","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/pcmr.12037","article-title":"Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions","volume":"26","author":"Maldi","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib55","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jnci\/djx198","article-title":"Nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic target in BRAF-mutated metastatic melanoma","volume":"110","author":"Audrito","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.cmet.2026.09.015_bib56","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1600-0463.2011.02733.x","article-title":"Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas","volume":"119","author":"Olesen","year":"2011","journal-title":"APMIS"},{"key":"10.1016\/j.cmet.2026.09.015_bib57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10428194.2025.2571199","article-title":"NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia","volume":"67","author":"Sanchez","year":"2026","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.cmet.2026.09.015_bib58","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2008-08-173369","article-title":"The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies","volume":"113","author":"Nahimana","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cmet.2026.09.015_bib59","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1158\/1078-0432.CCR-17-2575","article-title":"NAMPT is a potent oncogene in colon cancer progression that modulates cancer stem cell properties and resistance to therapy through Sirt1 and PARP","volume":"24","author":"Lucena-Cacace","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib60","first-page":"963","article-title":"NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma","volume":"42","author":"Guo","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cmet.2026.09.015_bib61","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-020-0513-5","article-title":"Targeting the NAD+ salvage pathway suppresses APC mutation-driven colorectal cancer growth and Wnt\/\u03b2-catenin signaling via increasing Axin level","volume":"18","author":"Ye","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.cmet.2026.09.015_bib62","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.cmet.2026.01.001","article-title":"Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML","volume":"38","author":"Jia","year":"2026","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib63","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s42255-020-0181-1","article-title":"MESH1 is a cytosolic NADPH phosphatase that regulates ferroptosis","volume":"2","author":"Ding","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib64","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41568-025-00864-1","article-title":"Decoding ferroptosis for cancer therapy","volume":"25","author":"Wahida","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib65","article-title":"Epigenetic regulation of cancer stemness","volume":"10","author":"Galassi","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cmet.2026.09.015_bib66","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/2159-8290.CD-24-0296","article-title":"The epigenetic hallmarks of cancer","volume":"14","author":"Esteller","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cmet.2026.09.015_bib67","article-title":"Complex roles of nicotinamide N-methyltransferase in cancer progression","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cmet.2026.09.015_bib68","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nchembio.1204","article-title":"NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink","volume":"9","author":"Ulanovskaya","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.cmet.2026.09.015_bib69","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1158\/1078-0432.CCR-16-1323","article-title":"NNMT silencing activates tumor suppressor PP2A, inactivates oncogenic STKs, and inhibits tumor forming ability","volume":"23","author":"Palanichamy","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071272","article-title":"RNA-mediated gene silencing of nicotinamide N-methyltransferase is associated with decreased tumorigenicity in human oral carcinoma cells","volume":"8","author":"Pozzi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cmet.2026.09.015_bib71","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41576-020-0270-8","article-title":"The evolving metabolic landscape of chromatin biology and epigenetics","volume":"21","author":"Dai","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.cmet.2026.09.015_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066283","article-title":"Enterocyte-specific inactivation of SIRT1 reduces tumor load in the APC(+\/min) mouse model","volume":"8","author":"Leko","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cmet.2026.09.015_bib73","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41388-018-0434-6","article-title":"SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1\/SIRT1 axis","volume":"38","author":"Li","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.cmet.2026.09.015_bib74","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cmet.2015.06.023","article-title":"Hypoxia induces production of L-2-hydroxyglutarate","volume":"22","author":"Intlekofer","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib75","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cmet.2015.06.021","article-title":"Hypoxia-mediated increases in L-2-hydroxyglutarate coordinate the metabolic response to reductive stress","volume":"22","author":"Oldham","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib76","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1158\/2159-8290.CD-13-0696","article-title":"L-2-hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer","volume":"4","author":"Shim","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cmet.2026.09.015_bib77","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.1158\/1078-0432.CCR-18-1727","article-title":"Biochemical and epigenetic insights into L-2-hydroxyglutarate, a potential therapeutic target in renal cancer","volume":"24","author":"Shelar","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib78","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib79","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1158\/0008-5472.CAN-22-1029","article-title":"Mitochondrial uncoupling induces epigenome remodeling and promotes differentiation in neuroblastoma","volume":"83","author":"Jiang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib80","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cmet.2026.09.015_bib81","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","article-title":"Inhibition of T cell proliferation by macrophage tryptophan catabolism","volume":"189","author":"Munn","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cmet.2026.09.015_bib82","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.4049\/jimmunol.164.7.3596","article-title":"Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation","volume":"164","author":"Hwu","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.cmet.2026.09.015_bib83","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1365-2567.2002.01526.x","article-title":"Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division","volume":"107","author":"Lee","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.cmet.2026.09.015_bib84","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.09.015_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24785-3","article-title":"3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine","volume":"12","author":"Clement","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2026.09.015_bib86","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/sj.cdd.4401073","article-title":"T cell apoptosis by tryptophan catabolism","volume":"9","author":"Fallarino","year":"2002","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.cmet.2026.09.015_bib87","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.cmet.2026.09.015_bib88","doi-asserted-by":"crossref","first-page":"19961","DOI":"10.1073\/pnas.1014465107","article-title":"Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism","volume":"107","author":"Nguyen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cmet.2026.09.015_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2026.09.015_bib90","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41593-019-0370-y","article-title":"Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39","volume":"22","author":"Takenaka","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cmet.2026.09.015_bib91","article-title":"Prognostic role of indoleamine 2,3-dioxygenase 1 expression in solid tumors: A systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib92","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib93","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib94","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cmet.2026.09.015_bib95","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.8235624","article-title":"Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38","volume":"262","author":"Howard","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.cmet.2026.09.015_bib96","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1074-7613(03)00266-8","article-title":"NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor","volume":"19","author":"Seman","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.cmet.2026.09.015_bib97","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41577-025-01161-6","article-title":"The diversity of CD8+ T cell dysfunction in cancer and viral infection","volume":"25","author":"Galluzzi","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cmet.2026.09.015_bib98","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.4049\/jimmunol.155.7.3353","article-title":"Characterization of cyclic adenosine diphosphate-ribose-induced Ca2+ release in T lymphocyte cell lines","volume":"155","author":"Guse","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.cmet.2026.09.015_bib99","doi-asserted-by":"crossref","first-page":"25602","DOI":"10.18632\/oncotarget.4693","article-title":"A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation","volume":"6","author":"Morandi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cmet.2026.09.015_bib100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1745988","article-title":"Regulating the regulators via targeting CD38 in the tumor microenvironment","volume":"17","author":"Dutta","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cmet.2026.09.015_bib102","article-title":"CT-based radiomics predicts CD38 expression and indirectly reflects clinical prognosis in epithelial ovarian cancer","volume":"10","author":"Yao","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.cmet.2026.09.015_bib103","doi-asserted-by":"crossref","first-page":"72","DOI":"10.7150\/jca.59730","article-title":"Integrative analysis identified CD38 as a key node that correlates highly with immunophenotype, chemoradiotherapy resistance, and prognosis of head and neck cancer","volume":"14","author":"He","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib104","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11302-022-09841-x","article-title":"NT5E gene and CD38 protein as potential prognostic biomarkers for childhood B-acute lymphoblastic leukemia","volume":"18","author":"da Silva Nunes","year":"2022","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.cmet.2026.09.015_bib105","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315989121","article-title":"CD38-RyR2 axis-mediated signaling impedes CD8+ T cell response to anti-PD1 therapy in cancer","volume":"121","author":"Kar","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cmet.2026.09.015_bib106","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137066","article-title":"Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes","volume":"5","author":"Woods","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.cmet.2026.09.015_bib107","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-23-0653","article-title":"A population of tumor-infiltrating CD4+ T cells co-expressing CD38 and CD39 is associated with checkpoint inhibitor resistance","volume":"29","author":"Mitra","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib108","doi-asserted-by":"crossref","first-page":"20332","DOI":"10.1002\/cam4.6619","article-title":"Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma","volume":"12","author":"Bisht","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.cmet.2026.09.015_bib109","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s42255-020-00298-z","article-title":"CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels","volume":"2","author":"Chini","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib110","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/s42255-020-00305-3","article-title":"Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages","volume":"2","author":"Covarrubias","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114102","article-title":"LXR\/CD38 activation drives cholesterol-induced macrophage senescence and neurodegeneration via NAD+ depletion","volume":"43","author":"Terao","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.cmet.2026.09.015_bib112","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41568-025-00858-z","article-title":"Ageing, immune fitness and cancer","volume":"25","author":"Dolan","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib113","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmet.2020.10.021","article-title":"NAD+ metabolism maintains inducible PD-L1 expression to drive tumor immune evasion","volume":"33","author":"Lv","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib114","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s44321-024-00051-z","article-title":"The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor","volume":"16","author":"Yang","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.cmet.2026.09.015_bib115","first-page":"187","article-title":"Immunosurveillance in clinical cancer management","volume":"74","author":"Kroemer","year":"2024","journal-title":"CA: Cancer J. Clin."},{"key":"10.1016\/j.cmet.2026.09.015_bib116","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cmet.2026.09.015_bib117","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmet.2017.10.006","article-title":"CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response","volume":"27","author":"Chatterjee","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109516","article-title":"NAD+ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells","volume":"36","author":"Wang","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.cmet.2026.09.015_bib119","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/hep.32658","article-title":"NAD + salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity","volume":"78","author":"Guo","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.09.015_bib120","article-title":"Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer","volume":"11","author":"Buqu\u00e9","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2026.09.015_bib121","first-page":"1","article-title":"MPA\/DMBA-driven mammary carcinomas","volume":"163","author":"Buqu\u00e9","year":"2021","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.cmet.2026.09.015_bib122","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001250","article-title":"Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice","volume":"8","author":"Selvanesan","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2011.12.005","article-title":"Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment","volume":"40","author":"Peled","year":"2012","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.cmet.2026.09.015_bib124","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade3341","article-title":"Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma","volume":"15","author":"Cichocki","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cmet.2026.09.015_bib125","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41590-019-0336-y","article-title":"Inflammatory macrophage dependence on NAD+ salvage is a consequence of reactive oxygen species-mediated DNA damage","volume":"20","author":"Cameron","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cmet.2026.09.015_bib126","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41590-018-0255-3","article-title":"Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation","volume":"20","author":"Minhas","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cmet.2026.09.015_bib127","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22923-5","article-title":"A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages","volume":"12","author":"Huffaker","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2026.09.015_bib128","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41590-023-01430-3","article-title":"CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions","volume":"24","author":"Liu","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cmet.2026.09.015_bib129","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2014-07-589069","article-title":"Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia","volume":"125","author":"Audrito","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cmet.2026.09.015_bib130","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41586-019-1173-8","article-title":"Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts","volume":"569","author":"Eckert","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.09.015_bib131","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41586-025-09303-5","article-title":"NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity","volume":"645","author":"Heide","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.09.015_bib132","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009281","article-title":"NAD+ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer","volume":"12","author":"Yang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib133","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.cmet.2024.05.013","article-title":"Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer","volume":"36","author":"Jiang","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110792","article-title":"The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62","volume":"39","author":"Linares","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.cmet.2026.09.015_bib135","first-page":"2843","article-title":"A Phase I study of CHS 828 in patients with solid tumor malignancy","volume":"8","author":"Hovstadius","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib136","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00280-009-1125-3","article-title":"Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data","volume":"65","author":"von Heideman","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cmet.2026.09.015_bib137","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1359-6349(08)72352-8","article-title":"418 POSTER A phase I trial of GMX1777: an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT)","volume":"6","author":"Pishvaian","year":"2008","journal-title":"Eur. J. Cancer Suppl."},{"key":"10.1016\/j.cmet.2026.09.015_bib138","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10637-007-9083-2","article-title":"The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor","volume":"26","author":"Holen","year":"2008","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.cmet.2026.09.015_bib139","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11523-026-01206-3","article-title":"First-in-human phase I study of KPT-9274, a first-in-class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies","volume":"21","author":"Razak","year":"2026","journal-title":"Target. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib140","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41416-018-0278-4","article-title":"Phase 1 study of ARQ 761, a beta-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis","volume":"119","author":"Gerber","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib141","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","article-title":"A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention","volume":"373","author":"Chen","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.09.015_bib142","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0167-8140(00)00165-1","article-title":"ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC)","volume":"55","author":"Bernier","year":"2000","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib143","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-13-1730","article-title":"Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer","volume":"20","author":"Janssens","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib144","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.2011.35.9315","article-title":"Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial","volume":"30","author":"Janssens","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib145","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib146","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.09.015_bib147","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2026.09.015_bib148","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib149","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib150","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.09.015_bib151","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.09.015_bib152","first-page":"1057","article-title":"WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells","volume":"62","author":"Wosikowski","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib153","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ccell.2015.11.006","article-title":"Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion","volume":"28","author":"Tateishi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib154","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1158\/0008-5472.CAN-20-1094","article-title":"Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma","volume":"80","author":"Li","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib155","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/1535-7163.MCT-24-0225","article-title":"Targeting NAD+ metabolism vulnerability in FH-deficient hereditary leiomyomatosis and renal cell carcinoma with the novel NAMPT inhibitor OT-82","volume":"24","author":"Najera","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cmet.2026.09.015_bib156","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1078-0432.CCR-13-0150","article-title":"Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors","volume":"20","author":"Chini","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib157","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1158\/0008-5472.CAN-14-0809","article-title":"Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption","volume":"74","author":"Chan","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib158","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00432-022-04124-9","article-title":"Targeting NAD metabolism regulates extracellular adenosine levels to improve the cytotoxicity of CD8+ effector T cells in the tumor microenvironment of gastric cancer","volume":"149","author":"Liu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib159","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-023-02631-2","article-title":"NAD pool as an antitumor target against cancer stem cells in head and neck cancer","volume":"42","author":"Navas","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cmet.2026.09.015_bib160","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-025-07672-3","article-title":"Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancer","volume":"16","author":"Kudo","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cmet.2026.09.015_bib161","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1074\/jbc.275.8.5416","article-title":"NAD(P)H: Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity","volume":"275","author":"Pink","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cmet.2026.09.015_bib162","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-43630-3","article-title":"Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma","volume":"14","author":"Nomura","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2026.09.015_bib163","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16112054","article-title":"Distinct capabilities in NAD metabolism mediate resistance to NAMPT inhibition in glioblastoma","volume":"16","author":"Perryman","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cmet.2026.09.015_bib164","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","article-title":"Targeting the DNA damage response in immuno-oncology: developments and opportunities","volume":"21","author":"Chabanon","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib165","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O'Neil","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.cmet.2026.09.015_bib166","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08530-5","article-title":"NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression","volume":"10","author":"Bian","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2026.09.015_bib167","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.cmet.2026.09.015_bib168","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cmet.2026.09.015_bib169","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2095949","article-title":"TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity","volume":"14","author":"Ugamraj","year":"2022","journal-title":"MAbs"},{"key":"10.1016\/j.cmet.2026.09.015_bib170","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/leu.2014.207","article-title":"The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting","volume":"29","author":"Vaisitti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.cmet.2026.09.015_bib171","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2019.11.005","article-title":"Targeting NAD+ synthesis to potentiate CD38-based immunotherapy of multiple myeloma","volume":"6","author":"Kennedy","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib172","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ccell.2014.10.002","article-title":"Inhibition of de novo NAD(+) synthesis by oncogenic URI causes liver tumorigenesis through DNA damage","volume":"26","author":"Tummala","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib173","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.aaf2693","article-title":"NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice","volume":"352","author":"Zhang","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cmet.2026.09.015_bib174","doi-asserted-by":"crossref","first-page":"9295","DOI":"10.1074\/jbc.RA118.005772","article-title":"Dihydronicotinamide riboside is a potent NAD+ concentration enhancer in vitro and in vivo","volume":"294","author":"Yang","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cmet.2026.09.015_bib175","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molmet.2019.09.013","article-title":"A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor","volume":"30","author":"Giroud-Gerbetant","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.cmet.2026.09.015_bib176","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202001826R","article-title":"Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice","volume":"35","author":"Zapata-P\u00e9rez","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.cmet.2026.09.015_bib177","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMoa2203086","article-title":"Nicotinamide for skin-cancer chemoprevention in transplant recipients","volume":"388","author":"Allen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.09.015_bib178","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3109\/02841869409098432","article-title":"Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON)","volume":"33","author":"Zackrisson","year":"1994","journal-title":"Acta Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib179","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1111\/bph.15096","article-title":"Possible mechanisms of cancer prevention by nicotinamide","volume":"178","author":"Buqu\u00e9","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cmet.2026.09.015_bib180","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2022.114826","article-title":"A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD+ metabolism","volume":"220","author":"Maric","year":"2023","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.cmet.2026.09.015_bib182","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-291X(86)90551-6","article-title":"Metabolic consequences of DNA damage: DNA damage induces alterations in glucose metabolism by activation of poly (ADP-ribose) polymerase","volume":"134","author":"Berger","year":"1986","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cmet.2026.09.015_bib183","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ccell.2025.12.005","article-title":"Cancer cell death: Cell-autonomous and immunogenic dimensions","volume":"44","author":"Galluzzi","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmet.2026.09.015_bib184","article-title":"Nicotinamide riboside alleviates cisplatin-induced peripheral neuropathy via SIRT2 activation","volume":"4","author":"Acklin","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.cmet.2026.09.015_bib185","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1038\/s43587-025-00947-6","article-title":"Emerging strategies, applications and challenges of targeting NAD+ in the clinic","volume":"5","author":"Zhang","year":"2025","journal-title":"Nat Aging"},{"key":"10.1016\/j.cmet.2026.09.015_bib186","article-title":"Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase","volume":"8","author":"Zhang","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cmet.2026.09.015_bib187","doi-asserted-by":"crossref","DOI":"10.1172\/JCI174824","article-title":"A metabolic signature for NADSYN1-dependent congenital NAD deficiency disorder","volume":"134","author":"Szot","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cmet.2026.09.015_bib188","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00622","article-title":"NAD metabolism in cancer therapeutics","volume":"8","author":"Yaku","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib189","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1581275","article-title":"Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications","volume":"15","author":"Vainer","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cmet.2026.09.015_bib190","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","article-title":"The technological landscape and applications of single-cell multi-omics","volume":"24","author":"Baysoy","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cmet.2026.09.015_bib191","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41576-023-00580-2","article-title":"Methods and applications for single-cell and spatial multi-omics","volume":"24","author":"Vandereyken","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.cmet.2026.09.015_bib192","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: therapeutic potential and persisting obstacles","volume":"21","author":"Tong","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cmet.2026.09.015_bib193","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41571-025-01075-1","article-title":"Optimizing CAR T cell therapy for solid tumours: a clinical perspective","volume":"22","author":"Li","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Cell Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413126003906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413126003906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:30:14Z","timestamp":1792215014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413126003906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":193,"alternative-id":["S1550413126003906"],"URL":"https:\/\/doi.org\/10.1016\/j.cmet.2026.09.015","relation":{},"ISSN":["1550-4131"],"issn-type":[{"value":"1550-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A context-dependent framework for targeting NAD metabolism in cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmet.2026.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}